Intellia Therapeutics (NTLA) stock soared 6.24% in pre-market trading on Monday, showing significant upward momentum ahead of the regular session.
The surge appears driven by a positive analyst action, with H.C. Wainwright analyst Mitchell Kapoor reiterating a Buy rating on the company and setting a price target of $25.00.
Such analyst endorsements often influence investor sentiment, particularly in pre-market activity, as they provide forward-looking assessments of a company's value and prospects.